Pfizer Yields 6.8%, Trades at 8.5X Earnings, and Has a Promising Late-Stage Weight Loss Drug. Why Are So Many Investors Still Ignoring the Stock?

Summary

Pfizer trades at an attractive valuation of 8.5X earnings with a 6.8% dividend yield and has a late-stage weight loss drug candidate in development, but remains undervalued by many investors.